Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Swedish Orphan Biovitrum
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00101582CT.gov Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stomatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palifermin (this asset) | Swedish Orphan Biovitrum | P3 | B · 60 |
| Methylene Blue | Mayo Clinic | P3 | BB |
| Datopotamab Deruxtecan | AstraZeneca | P4 | B |
| Dexasone | AstraZeneca | P4 | B |
| Meclocycline Sulfosalicylate | Mucosal Therapeutics | P2 | B |
| Prednisolone | US Oncology Research | P2 | B |
| Hydrocortisone | US Oncology Research | P2 | B |
| Thalidomide | National Institute of Nursing Research (NINR) | P2 | CCC |
| Mit-001 | MitoImmune Therapeutics | P2 | CCC |
+9 more in the Stomatitis cohort
Other indications for Palifermin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mucositis | — | P3 | BB · 64 |
| Non-Hodgkin Lymphoma | — | P4 | B · 63 |
| Plasma Cell Myeloma | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palifermin in Stomatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palifermin-stomatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →